Scott Coleman, PhD, is the Head of Nonclinical Development for Spero Therapeutics in Cambridge, MA. He was most recently at Cubist Pharmaceuticals as Senior Director of Discovery Toxicology and DMPK at where he worked on antibacterial and pain programs. During his nine years at Cubist, he oversaw the nonclinical discovery efforts from exploratory programs through candidate selection with multiple compounds successfully moving into the clinic. In addition, he worked closely with business development with due diligence on several opportunities including both Sivextro (tedizolid phosphate) and Zerbaxa (ceftolozane/tazobactam). Prior to his time at Cubist, Dr. Coleman had increasing roles of responsibility at Millennium Pharmaceuticals over six years working on inflammation and oncology programs both in discovery and clinical development.
Dr. Coleman received his BS in Toxicology from Northeastern University, his PhD in Toxicology from North Carolina State University, and completed his post-doctoral training at the University of Massachusetts Medical School. He is currently on the editorial board for The International Journal of Toxicology, the journal for The American College of Toxicology.